Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on October 19, 2009

Circulation. 2009
Published online before print October 19, 2009, doi: 10.1161/CIRCULATIONAHA.109.873265
A more recent version of this article appeared on November 3, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
120/18/1768    most recent
CIRCULATIONAHA.109.873265v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Patton, K. K.
Right arrow Articles by Kronmal, R. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patton, K. K.
Right arrow Articles by Kronmal, R. A.
Related Collections
Right arrow Other diagnostic testing
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Epidemiology
Right arrowRelated Article

Submitted on April 20, 2009
Accepted on July 31, 2009

N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation. The Cardiovascular Health Study

Kristen K. Patton MD, Patrick T. Ellinor MD, PhD, Susan R. Heckbert MD, PhD, Robert H. Christenson PhD, Christopher DeFilippi MD, John S. Gottdiener MD, and Richard A. Kronmal PhD*

From the Division of Cardiology (K.K.P.), Department of Epidemiology (S.R.H.), and Department of Biostatistics (R.A.K.), University of Washington, Seattle; Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachusetts General Hospital, Boston (P.T.E.); University of Maryland School of Medicine, Baltimore (R.H.C.); and Division of Cardiology, University of Maryland Medical Center, Baltimore (C.D., J.S.G.).

* To whom correspondence should be addressed. E-mail: kronmal{at}u.washington.edu.

Background—Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated with significant morbidity, mortality, and healthcare expenditures. Elevated B-type natriuretic peptide levels have been associated with the risk of heart failure, AF, and mortality.

Methods and Results—The relation between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and AF was studied in 5445 Cardiovascular Health Study participants with the use of relative risk regression for predicting prevalent AF and Cox proportional hazards for predicting incident AF. NT-proBNP levels were strongly associated with prevalent AF, with an unadjusted prevalence ratio of 128 for the highest quintile (95% confidence interval, 17.9 to 913.3; P<0.001) and adjusted prevalence ratio of 147 for the highest quintile (95% confidence interval, 20.4 to 1064.3; P<0.001) compared with the lowest. After a median follow-up of 10 years (maximum of 16 years), there were 1126 cases of incident AF (a rate of 2.2 per 100 person-years). NT-proBNP was highly predictive of incident AF, with an unadjusted hazard ratio of 5.2 (95% confidence interval, 4.3 to 6.4; P<0.001) for the development of AF for the highest quintile compared with the lowest; for the same contrast, NT-proBNP remained the strongest predictor of incident AF after adjustment for an extensive number of covariates, including age, sex, medication use, blood pressure, echocardiographic parameters, diabetes mellitus, and heart failure, with an adjusted hazard ratio of 4.0 (95% confidence interval, 3.2 to 5.0; P<0.001).

Conclusions—In a community-based population of older adults, NT-proBNP was a remarkable predictor of incident AF, independent of any other previously described risk factor.


Key words: arrhythmia • atrial fibrillation • natriuretic peptides


Related Article:

Clinical Summaries
Circulation 2009 120: 1743-1744. [Extract] [Full Text]